Merck KGaA’s Strategic Acquisition of SpringWorks Therapeutics Gains Momentum
03.02.2026 - 08:48:04 | boerse-global.de
Six months after finalizing its acquisition, Merck KGaA is hitting significant milestones in its integration of SpringWorks Therapeutics. The operational focus has now shifted decisively toward realizing synergies and launching new oncology treatments, following the delisting of SpringWorks’ shares from the Nasdaq last summer.
- Acquisition Cost: The transaction was valued at approximately $3.9 billion, equating to $47 per share.
- Strategic Focus: The deal expands Merck’s portfolio in rare cancers with the drugs OGSIVEO and EZMEKLY.
- Financial Target: Management anticipates the acquisition will begin contributing positively to adjusted earnings per share (EPS) by 2027.
The purchase granted Merck access to specialized Read more...
en | US85205L1070 | MERCK | boerse | 68546765 |
